高级搜索

多西他赛或奥沙利铂联合希罗达治疗晚期胃癌的疗效对比

刘丽英, 陈小兵, 罗素霞, 申维玺

刘丽英, 陈小兵, 罗素霞, 申维玺. 多西他赛或奥沙利铂联合希罗达治疗晚期胃癌的疗效对比[J]. 肿瘤防治研究, 2009, 36(04): 334-336. DOI: 10.3971/j.issn.1000-8578.2009.04.021
引用本文: 刘丽英, 陈小兵, 罗素霞, 申维玺. 多西他赛或奥沙利铂联合希罗达治疗晚期胃癌的疗效对比[J]. 肿瘤防治研究, 2009, 36(04): 334-336. DOI: 10.3971/j.issn.1000-8578.2009.04.021
LIU Li-ying, CHEN Xiao-bing, LUO Su-xia, SHEN Wei-xi. Curative Effects of Docetaxe or Oxaliplatin Combined with Xeloda in Advanced Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2009, 36(04): 334-336. DOI: 10.3971/j.issn.1000-8578.2009.04.021
Citation: LIU Li-ying, CHEN Xiao-bing, LUO Su-xia, SHEN Wei-xi. Curative Effects of Docetaxe or Oxaliplatin Combined with Xeloda in Advanced Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2009, 36(04): 334-336. DOI: 10.3971/j.issn.1000-8578.2009.04.021

多西他赛或奥沙利铂联合希罗达治疗晚期胃癌的疗效对比

详细信息
  • 中图分类号: R735.2

Curative Effects of Docetaxe or Oxaliplatin Combined with Xeloda in Advanced Gastric Cancer

  • 摘要: 目的 观察并比较多西他赛(TXT)联合希罗达(Xeloda)或奥沙利铂(LOHP)联合希罗达治疗晚期胃癌的近期疗效和副反应。 方法 41例患者随机分为两组,A组19例应用TXT联合Xeloda。B组22例应用LOHP联合Xeloda。均化疗2周期以上。 结果 41例均可评价, A组有效率(CR+PR)为52.63%,中位无进展生存期(PFS)为6.1月(95%CI:5.36~9.84),B组有效率(CR+PR)为54.55%, B组PFS为6.3月(95%CI:5.12~9.46),均无明显差异(χ2=0.015,P=0.902;Log Rank=1.99,P=0.1588)。两组副反应主要为骨髓抑制和胃肠道反应,均无化疗相关性死亡。 结论 两种方案对晚期胃癌患者疗效相当,副反应可以耐受。

     

    Abstract: Objective To evalulate the objective response rate, progression-free survival(PFS)and toxicity of Docetaxe or Oxaliplatin combined with Xeloda for advanced gastric cancer. Methods Forty-one patients with advanced gastric cancer were randomized and divided into two groups. Group A consisted of 19 patients received Docetaxe plus Xeloda and group B with 22 patients received Oxaliplatin plus Xeloda. The treatment was repeated every 3 weeks until disease progression or limiting toxicities. Two or more cycles chemotherapy were completed for all of patients. Results Forty-one patients were assessable for efficacy and toxicities. In group A and B,the response rate (CR+PR) was 52.63% and 54.55 %,respectively. The median progression-free survival in group A was similar to that in group B (6.1 months vs. 6.3 months, Log Rank=1.99, P=0.1588). The most common adverse effects were myelosuppression and gastrointestinal response in each group. Myelosuppression in group A was moderately frequent compared with that in group B . On the contrary, the rate of mild neurotoxicity in group B was a little increased. No chemotherapy-related death was observed. Conclusion The effects of docetaxe or Oxaliplatin combined with Xeloda for advanced gastric cancer were comparable and appropriate with a well tolerance.

     

计量
  • 文章访问数:  2356
  • HTML全文浏览量:  23
  • PDF下载量:  487
  • 被引次数: 0
出版历程
  • 收稿日期:  2008-03-10
  • 修回日期:  2008-06-16
  • 刊出日期:  2009-05-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭